Get the Stockscreener App
1.035
2.50%
0.035
Ocugen Inc stock is traded at $1.035, with a volume of 4.54M.
It is up +2.50% in the last 24 hours and down -26.79% over the past month.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
See More
Previous Close:
$1.00
Open:
$1.06
24h Volume:
4.54M
Relative Volume:
0.67
Market Cap:
$350.98M
Revenue:
$4.47M
Net Income/Loss:
$-71.67M
P/E Ratio:
-4.4651
EPS:
-0.2318
Net Cash Flow:
$-59.58M
1W Performance:
-3.30%
1M Performance:
-26.79%
6M Performance:
-47.44%
1Y Performance:
-32.57%
1-Day Range:
$1.02
$1.09
1-Week Range:
$0.9701
$1.09
52-Week Range:
$0.97
$2.725
Ocugen Inc Stock (OCGN) Company Profile
Name
Ocugen Inc
Sector
Industry
Phone
484-328-4701
Address
11 GREAT VALLEY PARKWAY, MALVERN, PA
Compare OCGN vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OCGN
Ocugen Inc
|
1.035 | 339.11M | 4.47M | -71.67M | -59.58M | -0.2318 |
VRTX
Vertex Pharmaceuticals Inc
|
520.53 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
787.04 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
196.71 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
960.38 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
205.95 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ocugen Inc Stock (OCGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-26 | Initiated | Canaccord Genuity | Buy |
| Mar-11-26 | Initiated | Oppenheimer | Outperform |
| Oct-15-24 | Initiated | Maxim Group | Buy |
| Mar-01-23 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Aug-23-22 | Initiated | Mizuho | Buy |
| Jun-15-22 | Resumed | ROTH Capital | Buy |
| Jun-02-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-26-21 | Initiated | Noble Capital Markets | Outperform |
| Jun-11-21 | Downgrade | ROTH Capital | Buy → Neutral |
| May-07-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-09-21 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Feb-04-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
View All
Ocugen Inc Stock (OCGN) Latest News
OCGN Looks 22.0% Overvalued on GF Value™ - GuruFocus
Ocugen receives provisional approval for gene therapy in Bahamas By Investing.com - Investing.com Canada
Ocugen Announces Expanded Access Program for OCU400 in Retinitis Pigmentosa Following LARTA Provisional Approval - quiverquant.com
Ocugen Stockholders Approve Meeting Adjournment for Share Increase - The Globe and Mail
Ocugen stockholders approve adjournment of special meeting for share increase vote - Investing.com Nigeria
Why Is Ocugen (NASDAQ:OCGN) Back in Focus as Wall Street Balances Growth and Defensive Demand? - Kalkine Media
Form 8K Ocugen, Inc For: 23 September By Investing.com - Investing.com Nigeria
Ocugen Inc. stock falls Monday, underperforms market - MarketWatch
H.C. Wainwright Maintains Ocugen(OCGN.US) With Buy Rating, Maintains Target Price $9.5 - Moomoo
OCGN: Proposal to increase authorized shares delayed due to insufficient votes; adjournment approved - TradingView
OCGN: Proposal to increase authorized shares stalled; adjourned meeting set for further voting - TradingView
symbol__ Stock Quote Price and Forecast - CNN
Why Did OCGN Stock Rise Today? - Stocktwits
Ocugen Inc. stock rises Thursday, outperforms market - MarketWatch
Ocugen Targets Three Gene Therapy BLA Filings as Retinal Pipeline Advances - TradingView
Ocugen Inc. stock rises Monday, outperforms market - MarketWatch
Ocugen CEO Musunuri sells $589,109 in shares, priced $1.06-$1.31 By Investing.com - Investing.com Australia
Ocugen CEO Musunuri sells $589,109 in shares, priced $1.06-$1.31 - investing.com
Ocugen: Q3 Data Catalyst In Stargardt Disease Feels Critical (NASDAQ:OCGN) - Seeking Alpha
Analysts Offer Insights on Healthcare Companies: Zymeworks (ZYME), Axsome Therapeutics (AXSM) and Ocugen (OCGN) - The Globe and Mail
Ocugen to Share Ophthalmic Gene Therapy Progress - TipRanks
Ocugen Inc. stock falls Thursday, underperforms market - MarketWatch
OCGN Stock Slips As Traders Focus On Weak Financials - StocksToTrade
OCGN Stock Slips As Weak Financials Weigh On Momentum - timothysykes.com
Ocugen: My Hold Rating Continued On OCU410ST Advancement And Upcoming Catalysts (OCGN) - Seeking Alpha
What's Happening With Ocugen Stock Thursday? - TradingView
H.C. Wainwright cuts Ocugen stock price target to $9.50 on trial delay - Investing.com India
OCGN Maintains Buy by HC Wainwright & Co. -- Price Target Lowered to $9.50 - GuruFocus
Ocugen Inc. stock falls Wednesday, underperforms market - MarketWatch
An Ocugen (NASDAQ: OCGN) insider plans a stock sale; the exact size is detailed in an SEC notice - Stock Titan
OCGN Looks 32.9% Overvalued on GF Value™ Amid Phase 2/3 Trial Se - GuruFocus
Ocugen slips after Stargardt disease trial data (OCGN:NASDAQ) - Seeking Alpha
OCGN Stock Slides As Traders Focus On Cash Burn And Key Support - timothysykes.com
Ocugen doses first patient in phase 3 GA gene therapy trial - Glance by Eyes On Eyecare
Ocugen Announces US$40 Million Registered Direct Offering Priced at $2.00 Per Share - Minichart
Ocugen Inc. stock falls Tuesday, underperforms market - MarketWatch
Ocugen Inc (NASDAQ: OCGN) Stock Price, News & Analysis - Kalkine
Ocugen Doses First Patient in Phase 3 Trial of OCU410 for GA - cgtlive.com
Malvern’s Ocugen Starts Pivotal Trial for Eye Gene Therapy - MyChesCo
Ocugen stock edges higher as investors watch recent quarterly figures - AD HOC NEWS
Ocugen Stock Price Forecast. Should You Buy OCGN? - StockInvest.us
Ocugen (NASDAQ:OCGN) Penny Stock Nears Major Gene Therapy Catalyst - Kalkine Media
OCGN Advances Gene Therapy OCU410 In Phase III for Geographic Atrophy - Yahoo Finance
Ocugen Doses First Patient in Global Phase 3 Trial of OCU410 for Geographic Atrophy - Eyewire+
Ocugen Eases on Tests - Baystreet.ca
Ocugen doses first patient in phase 3 gene therapy trial for GA - Investing.com Canada
OCGN Looks 61.0% Overvalued on GF Value™ - GuruFocus
Ocugen Doses First Patient in Global Phase 3 ArMaDa3 Trial of OCU410 for Geographic Atrophy and Receives FDA RMAT Designation - Quiver Quantitative
Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration - Ocugen, Inc.
Ocugen Announces First Patient Dosed in Phase 3 - GlobeNewswire
Malvern Biotech Ocugen to Present New Eye Gene Therapy Data - MyChesCo
Ocugen Inc Stock (OCGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Ocugen Inc Stock (OCGN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Musunuri Shankar | Chief Executive Officer |
Sep 09 '26 |
Sale |
1.12 |
57,264 |
64,136 |
1,088,035 |
3.71%
0.95%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):